The researchers demonstrated that IL-9-producing T cells activated via the ST2-IL-33 pathway (referred to as T9IL-33 cells) were capable of enhancing GVL activity while simultaneously reducing GVHD. The gene discussed is IL33; the disease is graft versus host disease.